Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5087478 | 0.82 | NMT1 (0.41) | F2NMT1AVPR1BAVPR1AMEN1 | |
| SCHEMBL492918 | 0.80 | F2 (0.39) | F2NMT1AVPR1BAVPR1AMEN1 | |
| SCHEMBL644440 | 0.73 | NMT1 (0.40) | F2NMT1AVPR1BAVPR1AMEN1 | |
| SCHEMBL4084739 | 0.72 | F2 (0.34) | F2NMT1AVPR1BAVPR1AMAPT | |
| SCHEMBL6838383 | 0.72 | F2 (0.48) | F2NMT1AVPR1BAVPR1AMEN1 | |
| SCHEMBL5125870 | 0.71 | HTT (0.43) | ALDH1A1 | |
| SCHEMBL4000323 | 0.69 | TSHR (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6438890 | 0.68 | AVPR1B (0.51) | F2NMT1AVPR1BAVPR1APLG | |
| SCHEMBL29381119 | 0.68 | NMT1 (0.49) | F2NMT1MEN1KMT2A | |
| SCHEMBL114242 | 0.68 | NMT1 (0.49) | F2NMT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | F2 1898/4885NMT1 2800/4885AVPR1B 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.